This is a randomized, phase 2, double-blind, placebo-controlled study of KER-012 in combination with background therapy in participants with PAH of World Health Organization (WHO) Group 1, functional class II-III. Participants will be randomly assigned in a 2:2:2:3 ratio to receive KER-012 (Dose A), KER-012 (Dose B), KER-012 (Dose C), or placebo by subcutaneous injection (SC) every 4 weeks for a period of 24 weeks in the placebo-controlled treatment period of the study while on background therapy.
Patient Stories
November 2, 2020
At 5-foot-8 and 295 pounds, Scott Strainge knew his weight was a contributing factor to his health issues. He was diagnosed with Type 2 diabetes eight years ago, which eventually progressed to a point where he needed seven different medications a day to keep his blood sugar and blood pressure under control.